FIELD: medicine.
SUBSTANCE: invention relates to field of medicine, in particular to hepatology, and can be used for prediction of fast virological response to therapy with pegylated interferon α and ribavirin in patients with chronic hepatitis C. For this purpose allele version of IL28B gene is identified and immunological assay is carried out. In case of presence of allele rs12979860CC/rs8099917TT immunoprediction coefficient 1 (IPC-1) is calculated by formula: IPC-1=2.774-0.833*[CD3+]-0.016*[CD4+]-0.063*[CD8+]-0.525*[CD19+], where [CD3+] is absolute content of CD3+ cells in 1 l of blood, [CD4+] is absolute content of CD3+/CD4+ cells in 1 l of blood, [CD8+] is absolute content of CD3+/CD8+ cells in 1 l of blood, [CD19+] is absolute content of CD19+ cells in 1 l of blood. If IPC-1 value is ≤1,5 development of fast virological response to standard therapy is predicted, in case of IPC-1>1.5 - its absence. If any other allele version is present IPC-2 is calculated by formula: IPC-2=3.994+0.014*[CD56+/ki-67+]-0.408*[CD25hi]-0.69*[CD25hi/FoxP3+], where [CD56+/ki-67+] is % of CD16+/CD56+/ki-67+ cells among blood lymphocytes, [CD25hi] is % of CD3+/CD25high cells among blood lymphocytes, [CD25hi/FoxP3+] is % of CD3+/CD25high/FoxP3+ cells among blood lymphocytes. If IPC-2 value is ≤3.0, fast development of fast virological response to standard therapy is predicted, in case of IPC-2 value >3.0 - its absence.
EFFECT: application of claimed method makes it possible to identify different shifts of immunograms by different allele versions of IL28B gene and provides possibility to predict presence or absence of fast virological response.
5 dwg, 2 tbl, 4 ex
